Crocs, Inc. vs Tempus AI — how do they compare? Crocs, Inc. trades at $116.68 (market cap $5.53B), while Tempus AI trades at $70 (market cap $12.77B). The key difference: Tempus AI is far larger — about 2.3× Crocs, Inc.'s market cap, and Crocs, Inc. is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Tempus AI for 22 Days on average.
| CROX | TEM | |
|---|---|---|
Market Cap | $5.53B | $12.77B |
Volume | 967,176 | 8,980,490 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $141.19 | $99.28 |
52-Week Low | $73.39 | $41.55 |
Typical Hold Time | 96 Days | 22 Days |
Enterprise Value | $7.04B | $13.40B |
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $116.84, down 2.81% today, amid bearish technical signals but strong fundamental valuation metrics. The stock shows attractive P/E of 10.23 and P/S of 1.46, with robust profitability margins including 57.47% gross margin and 42.3% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $4.55 surpassing the $4.35 estimate. The company maintains strong cash flow generation despite a net loss in 2025, with management focusing on product innovation and HEYDUDE brand repositioning.
CROX presents a compelling value opportunity with discounted valuation multiples relative to historical performance, though near-term technical weakness and competitive pressures warrant caution. Analyst consensus remains bullish with $136.78 price target representing 17% upside potential. Key risks include consumer discretionary spending sensitivity and execution challenges with brand diversification initiatives. The stock's current levels offer entry points for long-term investors seeking exposure to a profitable footwear company with strong brand recognition.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →